Launch week offerEnds in00h00m00s

annual Promonthly Pro

Amir Ashoorzadeh

Senior Research Fellow

University of Auckland

New Zealand

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in New Zealand

Articles (10)

Year:

2026

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (6)

David Ackerley

Professor and Programme Director, Biotechnology

Victoria University of Wellington

NEW ZEALAND

View details

Ben Krinkel

Professional Casual Staff

University of Auckland

NEW ZEALAND

View details

Chris Gwenin

Professor of Applied Health Sciences

Abertay University

UNITED KINGDOM

View details

Anna Wolfram

University of Tübingen

GERMANY

View details

Adam Patterson

Associate Professor

University of Auckland

NEW ZEALAND

View details

Jan Theys

University of Maastricht

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Amir Ashoorzadeh

Research Interests

Make your next move.

Explore related searches

Articles (10)

A cryptic allosteric pocket shapes isoform‐selective inhibition of human malic enzymes

The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach

Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications

Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit

Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling

Selectively Targeting Tumor Hypoxia with the Hypoxia-Activated Prodrug CP-506

Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours.

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3

Directed evolution of the B. subtilis nitroreductase YfkO improves activation of the PET-capable probe SN33623 and CB1954 prodrug

E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications

Collaborators (6)

David Ackerley

Ben Krinkel

Chris Gwenin

Anna Wolfram

Adam Patterson

Jan Theys

Make your next move.